The Medicines and Healthcare products Regulatory Authority has approved a new clinical trial to test whether psychedelic drugs can treat major depressive disorder. A novel prodrug of psilocin, MSP-1014, will be used in the trial designed by UK start-up Clerkenwell Health at its facility close to Harley Street. Developed by Canadian pharmaceuticals company Mindset Pharma…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
